Skip to main content
Bioceltix S.A. logo

Bioceltix S.A. — Investor Relations & Filings

Ticker · BCX ISIN · PLBCLTX00019 LEI · 259400QZD5JYK8SLZU51 WAR Manufacturing
Open in API
Filings indexed 270 across all filing types
Latest filing 2023-05-31 AGM Information
Country PL Poland
Listing WAR BCX

About Bioceltix S.A.

https://bioceltix.com/en/

Bioceltix S.A. is a biopharmaceutical company that develops stem cell-based medicinal products for veterinary use. The company focuses on creating therapies that utilize Mesenchymal Stem Cells (MSCs) as the active pharmaceutical ingredient. Its product pipeline is aimed at treating immunological and inflammatory conditions in companion animals, including dogs, cats, and horses. A key area of development includes treatments for conditions such as atopic dermatitis in dogs and degenerative joint disease.

Recent filings

Filing Released Lang Actions
Zwołanie ZWZA na dzień 27 czerwca 2023 roku - Content (PL)
AGM Information Classification · 1% confidence The document text is an official announcement (in Polish) by the Management Board ('Zarząd') of Bioceltix S.A. regarding the convening of an Ordinary General Meeting of Shareholders ('Zwyczajnego Walnego Zgromadzenia Akcjonariuszy') scheduled for June 27, 2023. The text details the full agenda ('porządek obrad'), which includes reviewing the 2022 annual report, financial statements, and voting on management discharge ('absolutorium'). This content directly relates to the formal proceedings and materials associated with an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R). The document is an announcement/notice about the AGM, not the presentation materials themselves, but AGM-R is the most specific category covering this event type.
2023-05-31 Polish
Zawiadomienie w trybie art. 19 ust. 1 Rozporządzenia MAR
Director's Dealing Classification · 1% confidence The document is titled "Powiadomienie o transakcji/transakcjach*, o którym mowa w art. 19 ust. 1 rozporządzenia MAR" (Notification of transaction(s) referred to in Article 19(1) of the MAR Regulation). Article 19 of the Market Abuse Regulation (MAR) specifically deals with transactions conducted by persons discharging managerial responsibilities (PDMRs) and persons closely associated with them. The content details a transaction involving shares ('Akcje Serii L') by an individual associated with the management ('Paweł Wielgus - Członek Zarządu') of Kvarko Group ASI Sp. z o.o. This type of insider transaction reporting directly corresponds to the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length is moderate (5157 chars), suggesting it is the report itself, not just an announcement of a report.
2023-05-30 Polish
Informacja o transakcji uzyskana w trybie art. 19 Rozporządzenia MAR - Content (PL)
Director's Dealing Classification · 1% confidence The document text is very short (577 characters) and explicitly states that the notification regarding a transaction (in this case, the acquisition of shares by an entity closely related to a Board Member) is attached to the current report ('Powiadomienie, o którym mowa powyżej, stanowi załącznik do raportu bieżącego.'). This structure—a brief announcement referencing an attached or detailed document—strongly suggests a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS), based on the 'MENU VS MEAL' rule. The content specifically details a transaction involving a member of management/board (Paweł Wielgus) and related parties, which is typically covered under insider dealing (DIRS) or major shareholding (MRQ). However, since the text itself is just the announcement of the notification being attached, and it concerns a transaction by a director/related party, it is most closely related to Director's Dealing (DIRS) or a general regulatory filing (RNS). Given the specific nature of the transaction involving a Board Member, DIRS is a strong candidate if the attached document is the actual transaction report. If the document is merely announcing the filing of the MAR Article 19 notification, RNS is the safest fallback. Since the content describes the notification of a transaction by a person closely associated with a Board Member (Art. 19 MAR), this falls under insider dealing rules. I will classify it as DIRS (Director's Dealing) as the subject matter is insider trading notification, even though the text is an announcement of the filing itself. If DIRS was not available, RNS would be the choice. Given the specific nature of the content (MAR Art. 19 notification regarding a Board Member's related party transaction), DIRS is the most specific fit for the *subject matter* being announced.
2023-05-30 Polish
Treść uchwały emisyjnej z dnia 29.05.2023 r.
Capital/Financing Update Classification · 1% confidence The document is a formal resolution ('PROTOKÓŁ POSIEDZENIA ZARZĄDU' - Minutes of the Management Board Meeting) from Bioceltix S.A. dated May 29, 2023. The core subject of the resolution (Uchwała nr 1/05/2023) is the decision to increase the share capital ('podwyższenia kapitału zakładowego Spółki') by issuing new shares (Series L) and subsequently amending the company's articles of association ('zmiany statutu Spółki'). It also details the exclusion of pre-emptive rights and the intention to seek admission of these shares to trading on a regulated market (GPW). This action directly relates to fundraising, capital structure changes, and the issuance of new shares. Based on the definitions, 'Capital/Financing Update' (CAP) is the most appropriate classification for a formal resolution detailing a capital increase and share issuance plan. It is not an Earnings Release (ER), Interim Report (IR), or a general regulatory announcement (RNS), as it is a specific corporate action document.
2023-05-30 Polish
Podjęcie przez Zarząd Spółki uchwały w sprawie podwyższenia kapitału zakładowego w granicach kapitału docelowego, zawarcie umowy objęcia akcji i podsumowanie subskrypcji - Content (PL)
Capital/Financing Update Classification · 1% confidence The document text is a formal announcement from the Management Board ('Zarząd') of Bioceltix S.A. detailing a resolution to increase the share capital ('podwyższenia kapitału zakładowego') through the issuance of new shares ('emisji nowych akcji zwykłych na okaziciela serii L'). It specifies the number of shares, the issue price, the total value, and the associated issuance costs. This content directly relates to fundraising, financing activities, and changes in the capital structure. This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple dividend notice (DIV).
2023-05-30 Polish
Zmienione zawiadomienie w trybie art. 19 ust. 1 Rozporządzenia MAR
Director's Dealing Classification · 1% confidence The document is titled "Powiadomienie o transakcji/transakcjach*, o którym mowa w art. 19 ust. 1 rozporządzenia MAR" (Notification of a transaction(s) referred to in Article 19(1) of the MAR Regulation). Article 19 of the Market Abuse Regulation (MAR) mandates reporting of transactions conducted by persons discharging managerial responsibilities (PDMRs) and persons closely associated with them. The content details a transaction involving 'Akcje Serii L' (Series L Shares) by an entity closely associated with a Board Member ('Paweł Wielgus - Członek Zarządu'). This directly corresponds to the definition of Director's Dealing (insider trades by directors/executives). The specific code for this is DIRS.
2023-05-30 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.